AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$LIVN

LivaNova forecasts 2026 revenue growth of 9%-10% while raising EPS guidance to $4.40-$4.50 (NASDAQ:LIVN)

LivaNova (LIVN) reported Q3 2026 revenue growth of 9-10%, raising EPS guidance to $4.40-$4.50. CEO Vladimir Makatsaria cited strong demand for cardiopulmonary and epilepsy technologies across all regions.

Original reporting
seekingalpha.com
Published Nov 4, 2026, 7:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 7:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$LIVN
Bullish
high confidence
Mentioned
$LIVN
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$LIVNBullishHigh
01

Why it matters

The raised guidance signals stronger demand and execution, likely supporting the stock price.

02

Market read

First‑report guidance lift for a mid‑cap med‑tech firm, actionable for traders today.

03

What to watch

Potential regulatory or reimbursement risks for its cardiopulmonary and epilepsy products.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

LivaNova is a medical‑technology company focused on cardiopulmonary and epilepsy devices.

Company-level read

Ticker impact

$LIVNBullishHigh confidence
Context

LivaNova raised its 2026 EPS guidance to $4.40‑$4.50 and forecast revenue growth of 9%‑10%, a fresh disclosure.

Expected impact

likely upside as the market prices in higher earnings expectations

Evidence & confidence

New guidance is above prior expectations, prompting buying interest.

Market effects

Sector

Medical device sector may see modest lift from LivaNova's upbeat outlook.

Regional

U.S. healthcare stocks could benefit in early trading.

Global

Limited to investors tracking med‑tech earnings.

Counterpoint

What could challenge this read

If guidance already priced in, the stock may face short‑term profit taking.

Key entities

  • Executive
    Vladimir Makatsaria

    CEO of LivaNova who commented on the quarter's performance.

Read at source← All news

StoryLivaNova posts Q3 2026 earnings beat and lifts full‑year revenue and EPS guidance

Also covered by

6 outlets

Related articles

$LIVNMed

LivaNova PLC (LIVN) (Q3 2026) Earnings Call Highlights: Double-Digit Growth Fuels

LivaNova PLC (LIVN) reported Q3 2026 earnings with adjusted free cash flow declining to $56M from $62M YoY. SG&A expenses rose to $136M from $123M, and a $400M payment shifted to Q4, creating cash flow uncertainty. The company expects 1% FX tailwind but $5M tariff headwinds. Cardiopulmonary growth remains strong, with double-digit increases, and the next-gen oxygenator launch is on track for 2028.

finance.yahoo.com
$LIVNMed

LivaNova PLC Q3 2026 Earnings Call Summary

LivaNova PLC raised its full-year 2026 revenue guidance to 9-10% growth and adjusted EPS to $4.40-$4.50. Growth was driven by record Essence heart-lung machine placements, epilepsy volume growth, and reduced discounting. The company plans to enter the obstructive sleep apnea (OSA) market in 2027 and expects double-digit capacity expansion in 2027 due to new manufacturing lines. Management highlighted strong demand for oxygenators and strategic initiatives to support future growth.

finance.yahoo.com
$LIVNMed

Mizuho raises Livanova stock price target on Essenz placements

Mizuho raised its price target for Livanova (LIVN) to $115 from $95, citing strong U.S. Cardiopulmonary segment growth and Essenz placements. The stock has risen 48% in the past year, trading at $96.59. Livanova reported Q3 2026 earnings of $1.23 per share, beating estimates, and raised its full-year outlook. Jefferies also increased its price target to $120.

investing.com
$LIVNHighAI 8/10

Jefferies raises Livanova stock price target to $120 on guidance

Jefferies increased its price target for LivaNova (NASDAQ:LIVN) to $120 from $100, maintaining a Buy rating. The company reported Q3 sales of $393M, up 10%, and EPS of $1.23, up 20%, both beating estimates. LivaNova raised its full-year sales growth guidance to 9-10% and EPS guidance to $4.40-$4.50. The stock has a market cap of $5.33B and a PEG ratio of 0.12, according to InvestingPro.

investing.com